UK government prepares no-deal Brexit express medicines serviceThe UK’s Department of Health and Social Care is setting up a service to deliver emergency medicines into Share XUK government prepares no-deal Brexit express medicines servicehttps://pharmaphorum.com/news/uk-government-prepares-no-deal-express-medicines-service/
Weekly roundup: Are actions stronger than words for Johnson and the NHS?It’s usually important for a new Conservative Party prime minister to make pledges within their first month in Share XWeekly roundup: Are actions stronger than words for Johnson and the NHS?https://pharmaphorum.com/views-and-analysis/weekly-roundup-are-actions-stronger-than-words-for-johnson-and-the-nhs/
Science sector lauds UK’s visa scheme, but repeats no-deal Brexit warningBoris Johnson has ordered a new fast-track visa scheme to make it easier for top scientists to work Share XScience sector lauds UK’s visa scheme, but repeats no-deal Brexit warninghttps://pharmaphorum.com/news/science-sector-lauds-uks-visa-scheme-but-repeats-no-deal-brexit-warning/
Boris Johnson announces £1.8bn cash boost for NHSNew UK prime minister Boris Johnson has pledged a £1.8 billion cash injection for the NHS as he Share XBoris Johnson announces £1.8bn cash boost for NHShttps://pharmaphorum.com/news/boris-johnson-announces-1-8bn-cash-boost-for-nhs/
EMA resolves dispute over pricey Canary Wharf tenancyAfter months of wrangling, the EMA finally has a solution to the £500 million financial liability it has Share XEMA resolves dispute over pricey Canary Wharf tenancyhttps://pharmaphorum.com/news/ema-resolves-dispute-over-pricey-canary-wharf-tenancy/
Nine for 2019: Challenges impacting pharmaAs we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping Share XNine for 2019: Challenges impacting pharmahttps://pharmaphorum.com/r-d/views-analysis-r-d/nine-for-2019-challenges-impacting-pharma/
Working with EU is ‘preferred option’ post-Brexit says MHRA chiefThe outgoing chief executive of the UK’s drugs regulator has said that the country’s “preferred option” is to Share XWorking with EU is ‘preferred option’ post-Brexit says MHRA chiefhttps://pharmaphorum.com/news/working-with-eu-is-preferred-option-post-brexit-says-mhra-chief/
BI chief “regrets” Brexit, but continues to invest in UKThe head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country Share XBI chief “regrets” Brexit, but continues to invest in UKhttps://pharmaphorum.com/news/bi-chief-regrets-brexit-but-continues-to-invest-in-uk/
UK pharma calls for temporary drug export ban after no-deal BrexitThe UK pharma industry has called for a temporary ban on drug exports in the event of a Share XUK pharma calls for temporary drug export ban after no-deal Brexithttps://pharmaphorum.com/news/uk-pharma-calls-for-temporary-drug-export-ban-after-no-deal-brexit/
